Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics, Inc. - Common Stock
(NQ:
RVNC
)
3.650
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Hormel Foods Reports Upbeat Earnings, Joins Pure Storage, Okta, Papa John's International And Other Big Stocks Moving Higher On Thursday
February 29, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
February 28, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
What 10 Analyst Ratings Have To Say About Revance Therapeutics
November 22, 2023
Via
Benzinga
Revance Therapeutics: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
Revance Therapeutics's Earnings Outlook
November 07, 2023
Via
Benzinga
Earnings Scheduled For February 28, 2024
February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
Via
Benzinga
Earnings Outlook For Revance Therapeutics
February 27, 2024
Via
Benzinga
The Latest Analyst Ratings for Revance Therapeutics
November 06, 2023
Via
Benzinga
Analyst Ratings for Revance Therapeutics
October 11, 2023
Via
Benzinga
Revance to Participate in Upcoming Investor Conferences
February 21, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 02, 2024
Via
Benzinga
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
February 02, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Philips Reports Q4 Results, Joins Ryanair And Other Big Stocks Moving Lower In Monday's Pre-Market Session
January 29, 2024
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
January 11, 2024
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
January 08, 2024
Via
Benzinga
Boeing, Pacific Biosciences of California And Other Big Stocks Moving Lower On Monday
January 08, 2024
U.S. stocks traded mixed, with the Dow Jones index falling around 80 points on Monday. Shares of The Boeing Company (NYSE: BA) fell during Friday’s session after an exit door blew out of a 737 aircraft...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 08, 2024
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...
Via
Benzinga
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
January 08, 2024
From
Revance Therapeutics, Inc.
Via
Business Wire
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
December 12, 2023
Consumer advocacy group Public Citizen has filed a petition with the FDA, urging the agency to demand stronger warnings regarding the risk of a potentially fatal muscle-paralyzing disease linked to...
Via
Benzinga
Exposures
Product Safety
Why AMC Entertainment Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 09, 2023
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results.
Via
Benzinga
AerSale, Topgolf Callaway Brands, Digital Turbine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
November 09, 2023
U.S. stock futures traded mostly higher this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
November 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
November 08, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Participate in Upcoming Investor Conferences
November 06, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
November 01, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
October 26, 2023
From
Revance Therapeutics, Inc.
Via
Business Wire
Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions
September 20, 2023
Needham analyst Serge Belanger reiterated a Buy rating on Revance Therapeutics, Inc. (NASDAQ: RVNC),
Via
Benzinga
Pinterest To Rally Around 45%? Here Are 10 Other Analyst Forecasts For Wednesday
September 20, 2023
Rosenblatt increased the price target for Pinterest, Inc. (NYSE: PINS) from $35 to $38. Rosenblatt analyst Barton Crockett maintained a Buy rating. Pinterest shares rose 3.2% to close at $26.21 on...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.